Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis
Journal of Clinical Medicine · 29.01.2023 · 12 (3) · 1035
DOI: 10.3390/jcm12031035 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Clinical Medicine, online erschienen am 29.01.2023. Verfasst von Xuejun He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Eye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hubei Key Laboratories Opening Project, Natural Science Foundation of Hubei Province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Submacular hemorrhage (SMH) is the accumulation of blood in the macular area that can severely damage the macular structure and visual function. Recently, the intraocular administration of tissue plasminogen activator (TPA) with anti-vascular endothelial growth factor (anti-VEGF) drugs was reported to have a positive effect on SMH. This meta-analysis aimed to explore the efficacy and safety of the drug combination. We systematically searched the Web of Science, MEDLINE, EMBASE, and Cochrane Library databases and screened relevant full-length literature reports. The quality of the reports was assessed by two independent reviewers. The best-corrected visual acuity (BCVA) and foveal thickness (FT) were considered the main indicators of efficacy. RevMan 5.4 software was used for this meta-analysis. Twelve studies were analyzed, and the results showed that BCVA at 1 month (p < 0.001), 3 months (p < 0.001), 6 months (p < 0.001), and the last follow-up (p < 0.001) was improved relative to the preoperative value. The postoperative FT was lower than the preoperative FT (p < 0.001). No significant difference in efficacy was observed between subretinal and intravitreal TPA injections (p = 0.37). TPA with anti-VEGF drugs is safe for SMH treatment and can significantly improve BCVA and reduce FT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Eye Center, Renmin Hospital of Wuhan University, 238 Jiefang Road, Wuhan 430060, China.
ORCID-Profile: Xuejun He, Wenye Cao, Yiqiao Xing, Ning Yang
Förderung
- Hubei Key Laboratories Opening Project
- Natural Science Foundation of Hubei Province
- Fundamental Research Funds for the Central Universities
Zitieren
APA
He, X., Cao, W., Wang, Z., Zhang, N., Xu, K., Yu, L., Xing, Y., & Yang, N. (2023). Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis. Journal of Clinical Medicine, 12(3), 1035. https://doi.org/10.3390/jcm12031035
Vancouver
He X, Cao W, Wang Z, Zhang N, Xu K, Yu L, et al. Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis. Journal of Clinical Medicine. 2023;12(3):1035. doi:10.3390/jcm12031035
BibTeX
@article{He2023,
author = {He, Xuejun and Cao, Wenye and Wang, Zhiyi and Zhang, Ningzhi and Xu, Kexin and Yu, Lu and Xing, Yiqiao and Yang, Ning},
title = {Efficacy Evaluation of Tissue Plasminogen Activator with Anti-Vascular Endothelial Growth Factor Drugs for Submacular Hemorrhage Treatment: A Meta-Analysis},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {3},
pages = {1035},
doi = {10.3390/jcm12031035}
}
EUVIMED